Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP306 vs DT in Japanese Adolescents
NCT02089347Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2014
- Primary completion
- Sep 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acellular pertussis vaccine in Tetanus, diphtheria and pertussis (2 arms), sponsored by Sanofi. Primary endpoints: Percentage of Participants With Diphtheria and Tetanus Post-vaccination Booster Response at Day 28, Percentage of Participants With Seroprotection to Diphtheria and Tetanus Antigens at Day 28 and 1 more. Started Mar 2014; status: completed.
02
Drugs
acellular pertussis vaccine
03
Conditions
Tetanusdiphtheriapertussis
Beyond the preview
Go deeper on NCT02089347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089347.